Show simple item record

dc.contributor.authorClarke, Noel W
dc.contributor.authorAli, Adnan
dc.contributor.authorIngleby, FC
dc.contributor.authorHoyle, Alex P
dc.contributor.authorAmos, CL
dc.contributor.authorAttard, G
dc.contributor.authorBrawley, CD
dc.contributor.authorCalvert, J
dc.contributor.authorChowdhury, S
dc.contributor.authorCook, A
dc.contributor.authorCross, W
dc.contributor.authorDearnaley, DP
dc.contributor.authorDouis, H
dc.contributor.authorGilbert, D
dc.contributor.authorGillessen, Silke
dc.contributor.authorJones, RJ
dc.contributor.authorLangley, RE
dc.contributor.authorMacNair, A
dc.contributor.authorMalik, Z
dc.contributor.authorMason, MD
dc.contributor.authorMatheson, D
dc.contributor.authorMillman, R
dc.contributor.authorParker, CC
dc.contributor.authorRitchie, AWS
dc.contributor.authorRush, H
dc.contributor.authorRussell, JM
dc.contributor.authorBrown, J
dc.contributor.authorBeesley, S
dc.contributor.authorBirtle, A
dc.contributor.authorCapaldi, L
dc.contributor.authorGale, J
dc.contributor.authorGibbs, S
dc.contributor.authorLydon, A
dc.contributor.authorNikapota, A
dc.contributor.authorOmlin, A
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorParikh, O
dc.contributor.authorProtheroe, A
dc.contributor.authorRudman, S
dc.contributor.authorSrihari, NN
dc.contributor.authorSimms, M
dc.contributor.authorTanguay, JS
dc.contributor.authorTolan, S
dc.contributor.authorWagstaff, J
dc.contributor.authorWallace, J
dc.contributor.authorWylie, James P
dc.contributor.authorZarkar, A
dc.contributor.authorSydes, MR
dc.contributor.authorParmar, MKB
dc.contributor.authorJames, ND
dc.date.accessioned2020-03-27T09:27:58Z
dc.date.available2020-03-27T09:27:58Z
dc.date.issued2020en
dc.identifier.citationClarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol. 2020;31:442.en
dc.identifier.pmid32067690en
dc.identifier.doi10.1016/j.annonc.2020.01.002en
dc.identifier.urihttp://hdl.handle.net/10541/622814
dc.description.abstractAddition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. [Ann Oncol. 2019]en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2020.01.002en
dc.titleCorrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003en
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchesteren
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-03-30T12:54:42Z


Files in this item

Thumbnail
Name:
32067690.pdf
Size:
129.0Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record